The New Humphrey Field Analyzer 3 from ZEISS

Article

The New HFA3 offers gold-standard perimetry performance with technological advances – such as automated trial lens correction with liquid lens technology – that are designed to save time and reduce errors.

The New Humphrey Field Analyzer 3 from ZEISS

Setting a New Standard for Efficient Visual Field Testing


The new Humphrey Field Analyzer 3 (HFA3) from ZEISS, is the next generation in visual field testing and analysis. The HFA3 is designed to accelerate clinic flow while delivering the same gold-standard testing strategies and test patterns.

The New HFA3 provides a streamlined and faster workflow with an array of new features designed to:

  • Reduce setup time with a single trial lens. Using liquid pressure, the new Liquid Trial Lens™ instantly delivers each patient’s refractive correction with the touch of a button.*

  • Save time with an intuitive new SmartTouch™ interface, which reduces the number of steps required for the technician to start a perimetry exam.

  • Accelerate clinic flow with equipment that can be learned quickly and operated easily.

  • Improve confidence in test results with RelEYE™, which allows doctors to instantly review the patient’s eye position, at any stimulus point. RelEYE data is available on the instrument and when reviewing test results with FORUM® Glaucoma Workplace.

  • Simplify test administration, with an easy-to-use kinetic graphical user interface with a full 180-degree field of view.

 

Find out more: www.zeiss.com/HFA3Contact us: www.meditec.zeiss.com/contacts

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Harvey Uy, MD, DPBO, FVRSP, speaks about artificial intelligence (AI) and optical coherence tomography (OCT) at the 2025 European Society of Retina Specialists (EURETINA) Congress.
EURETINA 2025: Boris Stanzel, MD, methotrexate is rocking the European retina landscape
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
© 2025 MJH Life Sciences

All rights reserved.